Because phosphorylation data of JAK1/2 and mTOR were not available in the TCGA database and in the published database of melanoma patients treated with ICB (GSE78220)34, precluding a direct examination of their activation, as an alternative approach, we constructed a list of genes that were reported to be direct downstream targets of mTOR and JAK1/2 in various tumor types, including bladder cancer, breast cancer, liver cancer, lymphoma, and chondrosarcoma. This evidence concerns the gene MTOR and urinary bladder carcinoma.